Duloxetine Capsule, Delayed Release
Product Images NDC 50090-7812

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-7812). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

This is a table displaying the number of patients with relapse over time for the treatment groups of placebo and duloxetine. The x-axis represents the time from randomization to relapse in days, while the y-axis shows the number of patients. The data seems to be measured at different time intervals up to 250 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a description of a clinical trial comparing a placebo with Duloxetine 60/120 mg once daily for pain management. The text also shows a graph indicating the percentage improvement in pain from baseline for different time intervals.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This is a graph showing the proportion of patients experiencing a relapse over time after randomization into two different treatments: placebo and duloxetine. The x-axis represents the time in days from randomization to relapse, and the y-axis shows the proportion of patients experiencing relapse. The graph indicates that duloxetine may be associated with a lower relapse rate compared to the placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

This text provides information on the percentage of patients improved with different doses of Duloxetine (60 mg BID, 60 mg QD, and 20 mg QD) compared to Placebo. It also mentions percent improvement in pain from the baseline.*

FDA Label Image

Figure4 (Duloxetine Fig4)

The text mentions the percentage of patients improved and the percent improvement in pain from baseline for different doses of Duloxetine and a placebo. This information is likely from a study or clinical trial evaluating the effectiveness of Duloxetine in managing pain.*

FDA Label Image

Figure5 (Duloxetine Fig5)

This text provides a comparison of the percentage of patients who improved using different treatments: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo. The data includes the percent improvement in pain from the baseline.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

Percentage of Patients Improved by taking Duloxetine 60 mg Once Daily compared to Placebo. The chart shows the percent improvement in pain from baseline, with a high of 100%, followed by varying degrees of improvement ranging from 10% to 90%.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This description appears to mention a medication dosage of Duloxetine 60/120 mg once daily for a certain use. The text also includes information on placebo and a measure of pain improvement.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This text includes information about a study comparing Duloxetine 60 mg once daily with a placebo in terms of pain improvement. The study shows data in terms of percent improvement in pain from baseline. The text also mentions different points in time for assessment (210, 220, 230, etc.). The study appears to be evaluating the effectiveness of Duloxetine compared to a placebo in treating pain.*

FDA Label Image

Structure (Duloxetine Structure)

FDA Label Image

Label Image (Lbl500907812)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.